该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分子化学药物，为MEK1/2 选择性抑制剂。 格隆汇2月5日丨复星医药(600196.SH)公布，公司控股子公司上海复星医药产业发展有限公司（称"复星 医药产业"）自主研发的复迈宁®（通用名：芦沃美替尼片；称"该药品"）用于治疗伴有症状、无法手 术的丛状神经纤维瘤（PN）的Ⅰ型神经纤维瘤病（NF1）成人患者（称"新增适应症"）的药品上市申请 获国家药品监督管理局受理并已获纳入优先审评程序。 ...

复星医药公告称，其控股子公司吉斯美（武汉）制药有限公司的环磷酰胺注射液药品注册申请获国家药 监局受理。该药品为集团自主研发，拟用于多种疾病治疗。截至2025年12月，集团针对该药品累计研发 投入约740万元。2024年，环磷酰胺注射剂在境内销售额约2.91亿元。该药品商业化生产前需获注册批 准，本次受理暂不对现阶段业绩产生重大影响，药品销售情况有不确定性。 ...

Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for the drug application of Fumainin® (Luwomeitini tablets) for new indications, which is now under priority review by the National Medical Products Administration [1] Group 1: Drug Development and Approval - The drug has been approved for two indications in China as of February 5, 2026, with one additional application accepted and two others in clinical trial stages [1] - The total R&D investment for this drug by the group is approximately 663 million yuan by December 2025 [1] Group 2: Market Potential - The global sales for MEK1/2 selective inhibitors are projected to be around 2.068 billion USD in 2024 [1] - Commercialization of the new indications is contingent upon obtaining regulatory approval, but the current acceptance does not impact the company's performance at this stage [1]

Market Overview - AMD's overnight drop of 17% triggered a significant decline in chip stocks, leading to a 1.95% drop in the Chinese concept index, which negatively impacted the Hong Kong stock market [1] - The Hang Seng Index fell by 340.88 points, or 1.27%, to 26,506.44 points, while the Hang Seng Tech Index decreased by 62.30 points, or 1.16%, to 5,304.14 points [1] - Major tech stocks like Tencent and Alibaba saw declines of nearly 3% and 2.5%, respectively, with Tencent's market value dropping below 500 billion [1] Company Performance - Xinda Biopharmaceuticals (01801.HK) projected total product revenue of approximately RMB 11.9 billion for 2025, reflecting a year-on-year growth of about 45% [2] - Lee & Man Paper Manufacturing (02314.HK) expects profits for 2025 to be between HKD 1.88 billion and HKD 2.00 billion, indicating a year-on-year increase of 38% to 47% [2] - ZTO Express (02057.HK) anticipates total revenue of RMB 48.5 billion to RMB 50 billion for 2025, representing a year-on-year growth of approximately 9.5% to 12.9% [2] - China Resources Cement (01313.HK) forecasts a year-on-year profit increase of about 115% to 135% for 2025, driven by reduced costs and impairment losses [2] Corporate Actions - Goldin Properties (00535.HK) reported a January contract sales total of approximately RMB 239 million, a year-on-year decrease of 61.82% [3] - Fosun International (00656.HK) plans to subscribe for additional registered capital of RMB 105 million in Shangmeng Technology, acquiring a 51.0879% stake post-increase [3] - Shanghai Pharmaceuticals (02607.HK) intends to publicly transfer its 30% stake in Bristol-Myers Squibb, with a minimum listing price of approximately RMB 1.023 billion [3] - China Coalbed Methane (08270.HK) completed the sale of 100% equity in Shanxi Qingshui Shuntai Energy Development [4] Investment Trends - The active repurchase of shares continues, with Kingsoft (03888.HK) repurchasing 1.0886 million shares for approximately HKD 29.99 million [9] - Xiaomi Group (01810.HK) repurchased 4.3 million shares for a total of HKD 146 million [10] - Kingdee International (00268.HK) repurchased 1 million shares for approximately HKD 11.1 million [11] Market Outlook - Guoyuan International's report suggests that the Hong Kong stock market may experience short-term volatility due to external factors, but maintains a positive long-term outlook [12] - CITIC Securities highlights the potential for new investment opportunities in emerging markets, despite risks from rising oil prices and long-term bond yields [12] - Galaxy Securities recommends focusing on technology, energy, precious metals, and consumer sectors for potential rebounds [13]

Core Viewpoint - Despite positive policy progress, the implementation of the commercial insurance innovative drug directory faces challenges [2] Group 1: Current Status of Innovative Drugs - Currently, basic medical insurance covers 44% of innovative drug sales costs, while commercial insurance only covers 7%, leaving nearly half of the costs to be borne by patients or other channels [2] - The first version of the commercial insurance innovative drug directory was released by the National Medical Insurance Administration in December 2025, officially implemented on January 1, 2026, covering five CAR-T products, including Fosun Pharma's CAR-T product Yikaida [2] Group 2: Bottlenecks in Implementation - Three main bottlenecks need to be overcome for the effective implementation of the commercial insurance innovative drug directory: 1. Deepening the "three medical collaborations" to create a dual-channel mechanism of "medical insurance + commercial insurance" [2] 2. Optimizing the process and mechanism connections, enhancing cooperation between insurance companies and regulatory bodies [3] 3. Strengthening patient education and awareness through collaboration between medical and insurance institutions [3] Group 3: Focus on Elderly Major Diseases - The rapid growth of the elderly population is leading to an increase in age-related diseases, such as central nervous system diseases and rare diseases, while the number of innovative drug companies in this field is limited [3] - The importance of payment support for innovative drug development for elderly diseases is emphasized, suggesting the use of medical insurance data for research and development [3][4] Group 4: Recommendations for Policy and Funding - Recommendations include creating a special fund for elderly disease research and development, lowering R&D thresholds to attract more entrepreneurs and investors, and supporting the inclusion of innovative drugs for elderly diseases in basic medical insurance and commercial health insurance directories [4] - The establishment of a milestone reward system for projects entering clinical phase II is suggested to address challenges in the elderly health sector [4] Group 5: Company Strategy and Global Collaboration - Fosun Pharma is actively seeking global collaborations and has announced multiple business development transactions, indicating a recognition of China's innovative capabilities internationally [5] - The company focuses on core areas such as oncology, immune inflammation, and central nervous system diseases, utilizing diverse methods like licensing and collaborative development to enhance its pipeline and market presence [5]

格隆汇2月4日丨根据联交所最新权益披露资料显示，2026年1月29日，复星医药(02196.HK)获BlackRock, Inc.在场内以每股均价20.8511港元增持好仓101.35万 股，涉资约2113.26万港元。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 有 | | | | | | | | | 份百分比 | | | | | | | | | ( 96 ) | | CS20260203E00525 | BlackRock, Inc. | 1001(L) | | 1,013,500(L) | HKD 20.8511 | 28.471.592(L) | 5.16(L)29/01/2026 | | | | | | | | 95.000(S) | 0.02(S) | | 股份代號: | ...

| 股份代號: | 02196 | | --- | --- | | 上市法國名稱: | 上海復星醫藥（集團）股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 04/01/2026 - 04/02/2026 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 有 | | | | | | | | | 份百分比 | | | | | | | | | ( 96 ) | | CS20260203E00525 | BlackRock, Inc. | 1001(L) | | 1,013,500(L) | HKD 20.8511 | 28.471.592(L) | 5.16(L)29/01/2026 | | | | | | | | 95.000(S) | 0.02(S) | 格隆汇2月4 ...

证券日报网讯2月4日，复星医药（600196）在互动平台回答投资者提问时表示，公司自1994年创立于上 海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医 疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承 载。在品牌管理方面，公司将基于多元的业务特征，兼顾行业特殊性、业务协同及市场品牌认知的统一 性，持续完善公司品牌架构体系。 ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：02196） NOTIFICATION LETTER 通知信函 As a non-registered shareholder, if you wish to receive Corporate Communications of the Company in electronic form, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares in the Company are held (co ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：02196） NOTIFICATION LETTER 通知信函 4 February 2026 Dear Registered Shareholders. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") — Notice of publication of circular of the 2026 first extraordinary general meeting and 2026 first H shareholders' class meeting, notice of the 2026 first ex ...